1
|
Kankuri E, Finckenberg P, Leinonen J, Tarkia M, Björk S, Purhonen J, Kallijärvi J, Kankainen M, Soliymani R, Lalowski M, Mervaala E. Altered acylcarnitine metabolism and inflexible mitochondrial fuel utilization characterize the loss of neonatal myocardial regeneration capacity. Exp Mol Med 2023; 55:806-817. [PMID: 37009793 PMCID: PMC10167339 DOI: 10.1038/s12276-023-00967-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2022] [Revised: 11/29/2022] [Accepted: 12/23/2022] [Indexed: 04/04/2023] Open
Abstract
Myocardial regeneration capacity declines during the first week after birth, and this decline is linked to adaptation to oxidative metabolism. Utilizing this regenerative window, we characterized the metabolic changes in myocardial injury in 1-day-old regeneration-competent and 7-day-old regeneration-compromised mice. The mice were either sham-operated or received left anterior descending coronary artery ligation to induce myocardial infarction (MI) and acute ischemic heart failure. Myocardial samples were collected 21 days after operations for metabolomic, transcriptomic and proteomic analyses. Phenotypic characterizations were carried out using echocardiography, histology and mitochondrial structural and functional assessments. In both groups, MI induced an early decline in cardiac function that persisted in the regeneration-compromised mice over time. By integrating the findings from metabolomic, transcriptomic and proteomic examinations, we linked regeneration failure to the accumulation of long-chain acylcarnitines and insufficient metabolic capacity for fatty acid beta-oxidation. Decreased expression of the redox-sensitive mitochondrial Slc25a20 carnitine-acylcarnitine translocase together with a decreased reduced:oxidized glutathione ratio in the myocardium in the regeneration-compromised mice pointed to a defect in the redox-sensitive acylcarnitine transport to the mitochondrial matrix. Rather than a forced shift from the preferred adult myocardial oxidative fuel source, our results suggest the facilitation of mitochondrial fatty acid transport and improvement of the beta-oxidation pathway as a means to overcome the metabolic barrier for repair and regeneration in adult mammals after MI and heart failure.
Collapse
Affiliation(s)
- E Kankuri
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - P Finckenberg
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - J Leinonen
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - M Tarkia
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - S Björk
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - J Purhonen
- Folkhälsan Research Center, Helsinki, Finland
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - J Kallijärvi
- Folkhälsan Research Center, Helsinki, Finland
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - M Kankainen
- Medical and Clinical Genetics, Faculty of Medicine, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
- Translational Immunology Research Program and Department of Clinical Chemistry, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - R Soliymani
- Helsinki Institute of Life Science (HiLIFE), Meilahti Clinical Proteomics Core Facility, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - M Lalowski
- Helsinki Institute of Life Science (HiLIFE), Meilahti Clinical Proteomics Core Facility, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Department of Gene Expression, Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, Poznań, Poland
| | - E Mervaala
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
| |
Collapse
|
2
|
Krebs R, Dhaygude K, Holmstrom E, Kankainen M, Syrjala S, Mattila P, Nykanen A, Lemstrom K. Platelet Transcriptome as a Liquid Biopsy for Acute Cellular Rejection After Heart Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
3
|
Krebs R, Holmström E, Dhaygude K, Kankainen M, Syrjälä S, Lukac J, Mattila P, Nykänen A, Lemström K. Platelet Transcriptome as a Liquid Biopsy for Rejection After Heart Transplantation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
4
|
Syrjälä S, Lahtiharju A, Simonen P, Pentikäinen M, Kankainen M, Kytölä S, Lemström K. Donor-Derived Cell-Free DNA in Cardiac Allograft Rejection Detection. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Krebs R, Holmström E, Dhaygude K, Kankainen M, Syrjälä S, Lukac J, Mattila P, Nykänen A, Lemström K. Effect of Donor Simvastatin Treatment on Gene Expression Profiles in Human Cardiac Allografts during Reperfusion. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
6
|
Krebs R, Holmström E, Dhaygude K, Kankainen M, Syrjälä S, Lukac J, Mattila P, Nykänen A, Lemström K. Effect of Donor Simvastatin Treatment on Gene Expression Profiles in Human Cardiac Allografts during Ischemia-Reperfusion Injury. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
7
|
Levä E, Syrjälä S, Kytölä S, Kankainen M, Krebs R, Lemström K. Donor-Derived Cell-Free DNA as an Early Noninvasive Biomarker of Cardiac Allograft Injury and Rejection in Human Heart Transplant Recipients. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
8
|
Krebs R, Kankainen M, Syrjälä S, Nykänen A, Lemström K. Platelet Transcriptome as a Marker for Rejection after Heart Transplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
9
|
Krebs R, Kankainen M, Holmström E, Dhaygude K, Lukac J, Ojala T, Mattila P, Nykänen A, Lemström K. Effect of Donor Simvastatin Treatment on Gene Expression Profiles in Human Cardiac Allografts during Ischemia-Reperfusion Injury. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
10
|
Simonen P, Kankainen M, Ojala T, Lehtonen J, Kankuri E, Kupari M. P1606Blood transcriptome profiling in suspected cardiac sarcoidosis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- P Simonen
- Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland
| | - M Kankainen
- University of Helsinki, Medical and Clinical genetics, Division of Genetics, Helsinki, Finland
| | - T Ojala
- University of Helsinki, Department of Pharmacology, Helsinki, Finland
| | - J Lehtonen
- Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland
| | - E Kankuri
- University of Helsinki, Department of Pharmacology, Helsinki, Finland
| | - M Kupari
- Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland
| |
Collapse
|
11
|
Krebs R, Kankainen M, Holmström E, Lukac J, Ojala T, Mattila P, Nykänen A, Lemström K. Donor Simvastatin Treatment Alters the Gene Expression Profile of Human Cardiac Allografts During Ischemia and Reperfusion. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
12
|
Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8 + T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology 2015; 4:e1017702. [PMID: 26140248 PMCID: PMC4485730 DOI: 10.1080/2162402x.2015.1017702] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 02/05/2015] [Accepted: 02/06/2015] [Indexed: 12/04/2022] Open
Abstract
Adenoviruses are excellent immunotherapeutic agents with a unique ability to prime and boost immune responses. Recombinant adenoviruses cause immunogenic cancer cell death and subsequent release of tumor antigens for antigen presenting cells, resulting in the priming of potent tumor-specific immunity. This effect may be further enhanced by immune-stimulating transgenes expressed by the virus. We report a case of a 38-year-old female with Stage 3 metastatic micropapillary serous carcinoma of the ovary. She was treated in a Phase I study with a granulocyte-macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, Ad5/3-D24-GMCSF (ONCOS-102). The treatment resulted in progressive infiltration of CD8+ lymphocytes into the tumor and concomitant systemic induction of several tumor-specific CD8+ T-cell populations. The patient was alive at the latest follow up more than 20 months after initiation of the study.
Collapse
Affiliation(s)
| | - T Ranki
- Oncos Therapeutics ; Helsinki, Finland
| | - T Joensuu
- Docrates Cancer Center ; Helsinki, Finland
| | - E Jäger
- Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany
| | - J Karbach
- Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany
| | - C Wahle
- Hämatologie-Onkologie; Krankenhaus Nordwest ; Frankfurt, Germany
| | - K Partanen
- Docrates Cancer Center ; Helsinki, Finland
| | - K Kairemo
- Docrates Cancer Center ; Helsinki, Finland
| | - T Alanko
- Docrates Cancer Center ; Helsinki, Finland
| | - R Turkki
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - N Linder
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - J Lundin
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - A Ristimäki
- Division of Pathology; HUSLAB and Haartman Institute; Helsinki University Central Hospital ; Helsinki, Finland ; Genome-Scale Biology; Research Programs Unit; University of Helsinki ; Helsinki, Finland
| | - M Kankainen
- Institute for Molecular Medicine Finland (FIMM) ; Helsinki, Finland
| | - A Hemminki
- University of Helsinki and Helsinki University Central Hospital; Cancer Gene Therapy Group ; Helsinki, Finland
| | - C Backman
- Oncos Therapeutics ; Helsinki, Finland
| | - K Dienel
- Oncos Therapeutics ; Helsinki, Finland
| | | | | | - T Hakonen
- Oncos Therapeutics ; Helsinki, Finland
| | - J Juhila
- Oncos Therapeutics ; Helsinki, Finland
| | | | - P Priha
- Oncos Therapeutics ; Helsinki, Finland
| | | | - S Pesonen
- Oncos Therapeutics ; Helsinki, Finland
| |
Collapse
|